Metabolic Efficacy and Safety of Once-Daily Pioglitazone Monotherapy in Patients with Type 2 Diabetes: A Double-Blind, Placebo-Controlled Study

Abstract

Pioglitazone is a novel oral anti-diabetic agent belonging to the thiazolidinedione class. Pioglitazone has been shown to be effective and well tolerated in the treatment of patients with type 2 diabetes, as it reduces insulin resistance and improves glycaemic control and abnormal lipid profiles. This double-blind, randomised, placebo-controlled study was conducted for further evaluation of the efficacy and tolerability of once-daily administration of pioglitazone monotherapy alongside dietary measures in patients with type 2 diabetes. Following a 10-week washout period, 251 patients received one of three treatment regimens for 26 weeks: placebo + diet (n = 84), pioglitazone 15 mg once-daily + diet (n = 89), or pioglitazone 30 mg once-daily + diet (n = 78). Pioglitazone, both 15 and 30 mg/day, in addition to dietary control, was associated with significant reductions (vs. placebo) in mean levels of both glycosylated haemoglobin (HbA_1C) and fasting blood glucose (FBG). HbA_1C was reduced by 0.92 % and 1.05 %, respectively, and FBG was reduced by 34.3 and 36.0 mg/dl, respectively, compared with the control group. Pioglitazone at 15 and 30 mg/day significantly reduced postprandial blood glucose levels at all visits (- 163 and - 165 mg/dl/hour, respectively) compared with an increase of 47.7 mg/dl/hour on placebo. The profile and frequency of adverse events were similar in all treatment groups. These results indicate that pioglitazone monotherapy together with dietary control is both effective and safe in patients with type 2 diabetes.

Pioglitazone - Type 2 Diabetes - Insulin Resistance - Glycaemic Control

References

• 1 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 2 Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.  Diabetes Res Clin Pract. 1995;  28 103-117
• 3 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-986
• 4 Groop L C. Sulfonylureas in NIDDM.  Diabetes Care. 1992;  15 737-754
• 5 Karam J. Pancreatic hormones and diabetes mellitus. In: Strewler GJ, Greenspan FS (eds) Basic and Clinical Endocrinology. Stamford; Appleton & Lange 1997: 595-663
• 6 Chang A Y, Wyse B M, Gilchrist B J, Peterson T, Diani A R. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats.  Diabetes. 1983;  32 830-838
• 7 Kaneko T. Evaluation of the clinical efficacy of an insulin resistance-improving drug, AD-4833, in patients with NIDDM on diet therapy alone.  Jpn J Clin Exp Med. 1997;  74 1217-1226
• 8 Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Clinical evaluation of the monotherapy by a new oral hypoglycemic drug, CS-045, in patients with non-insulin-dependent diabetes mellitus: placebo-controlled, double-blind comparative study.  J Clin Ther Med. 1993;  9 (Suppl. 3) 61-93
• 9 Saltiel A R, Olefsky J M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes.  Diabetes. 1996;  45 1661-1669
• 10 Willson T M, Cobb J E, Cowan D J, Wiethe R W, Correa I D, Prakash S R, Beck K D, Moore L B, Kliewer S A, Lehmann J M. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.  J Med Chem. 1996;  39 665-668
• 11 Hayakawa T, Shiraki T, Morimoto T, Shii K, Ikeda H. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats.  Biochem Biophys Res Commun. 1996;  223 439-444
• 12 Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin-resistant animals.  Arzneimittelforschung. 1990;  40 156-162
• 13 Iwanishi M, Kobayashi M, Shigeta Y. Effect of pioglitazone on insulin receptors of high-fat-fed rats.  J Jpn Diabetic Soc. 1992;  35 739-745
• 14 Iwanishi M, Kobayashi M. Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats.  Metabolism. 1993;  42 1017-1021
• 15 Kemnitz J W, Elson D F, Roecker E B, Baum S T, Bergman R N, Meglasson M D. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys.  Diabetes. 1994;  43 204-211
• 16 Kobayashi M, Iwanishi M, Egawa K, Shigeta Y. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase.  Diabetes. 1992;  41 476-483
• 17 Odaka H, Sugiyama Y, Ikeda H. Effect of pioglitazone on sucrose-deteriorated diabetic states in spontaneously diabetic GK rats.  J Jpn Diabetic Soc. 1991;  34 523-530
• 18 Sugiyama Y, Taketomi S, Shimura Y, Ikeda H, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.  Arzneimittelforschung. 1990;  40 263-267
• 19 Kruszynska Y T, Mukherjee R, Jow L, Dana S, Paterniti J R, Olefsky J M. Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non- insulin-dependent diabetes mellitus.  J Clin Invest. 1998;  101 543-548
• 20 Martin G, Schoonjans K, Staels B, Auwerx J. PPAR-gamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes.  Atherosclerosis. 1998;  137 (Suppl.) 75-80
• 21 Matsuhisa M, Shi Z Q, Wan C, Lekas M, Rodgers C D, Giacca A, Kawamori R, Vranic M. The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs.  Diabetes. 1997;  46 224-231
• 22 Brockley M R, Schneider R L. The onset of blood glucose response in patients with type 2 diabetes treated with pioglitazone.  Diabetes. 2000;  49 (Suppl. 1) A400 [abstract]
• 23 Ban J, Miyajima T, Tsumura Y, Inoue T, Nakamura T, Imamura A, Oe M. Combination study of AD-4833, insulin resistance-improving drugs and SU agents. Effect of SU on serum concentrations.  Jpn J Clin Exp Med. 1997;  74 1217-1226
• 24 Lebrizzi R, Egan J W, on behalf of the Pioglitazone 010 014 and 027 Study Groups. The HbA1c and blood glucose response to pioglitazone in combination with another antidiabetic agent in patients with type 2 diabetes.  Diabetes. 2000;  49 (Suppl. 1) A463 [abstract]
• 25 Einhorn D, Rendell M, Rosenzweig J, Egan J W, Mathisen A L, Schneider R L, on behalf of the Pioglitazone 027 Study Groups. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study.  Clin Ther. 2000;  22 1395-1409
• 26 Rubin C, Egan J W, Schneider R L, on behalf of the Pioglitazone 014 Study Groups. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes.  Diabetes. 1999;  48 (Suppl. 1) A110 [abstract]
• 27 Schneider R, Egan J, Houser V, on behalf of the Pioglitazone 010 Study Groups. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes.  Diabetes. 1999;  48 (Suppl. 1) A106 [abstract]
• 28 Aronoff S, Rosenblatt S, Braithwaite S, Egan J W, Mathisen A L, Schneider R L, on behalf of the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month, randomized, placebo-controlled, dose-response study.  Diabetes Care. 2000;  23 1605-1611
• 29 Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes (EASD) Statement 1995. Recommendations for the nutritional management of patients with diabetes mellitus.  Diab Nutr Metab. 1995;  8 186-189
• 30 Nutrition Committee of the German Diabetes Society. Ernährungsempfehlungen für Diabetiker.  Diab Stoffw. 1995;  4 431-433
• 31 Kaneko T, Baba S, Toyota T. Dose-finding study of AD-4833 in patients with NIDDM on diet therapy alone: double-blind, comparative study on four dosages.  Jpn J Clin Exp Med. 1997;  74 1250-1277
• 32 Egan J, Rubin C, Mathisen A, on behalf of the Pioglitazone 010 Study Group. Combination therapy with pioglitazone and metformin in patients with type 2 diabetes.  Diabetes. 1997;  48 (Suppl. 1) A117 [abstract]
• 33 Kipnes M S, Krosnick A, Rendell M S, Egan J W, Mathisen A L, Schneider R L. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.  Am J Med. 2001;  111 10-17
• 34 Feinglos M N, Bethel M A. Treatment of type 2 diabetes mellitus.  Med Clin North Am. 1998;  82 757-790
• 35 Olefsky J. Insulin resistance. In: Porte D, Sherwin RS (eds) Ellenberg & Rifkin's Diabetes Mellitus. Stamford; Appleton & Lange 1997: 513-552
• 36 Kraegen E W, Cooney G J, Ye J, Thompson A L. Triglycerides, fatty acids and insulin resistance-hyperinsulinemia.  Exp Clin Endocrinol Diabetes. 2001;  109 S516-526
• 37 Rossetti L. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus.  Clin Invest Med. 1995;  18 255-260
• 38 Ferrannini E, Galvan A Q, Gastaldelli A, Camastra S, Sironi A M, Toschi E, Baldi S, Frascerra S, Monzani F, Antonelli A, Nannipieri M, Mari A, Seghieri G, Natali A. Insulin: new roles for an ancient hormone.  Eur J Clin Invest. 1999;  29 842-852
• 39 Hanefeld M, Göke B. Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes.  Exp Clin Endocrinol Diabetes. 2000;  108 256-266